Optimizing the clinical and financial aspects of disease management when covering an infused drug product under the pharmacy and medical benefit.
October 12th 2020EP. 1: Choosing Drug-related Routes of Administration
October 12th 2020EP. 2: Routes of Administration: Adherence and Persistence
October 12th 2020EP. 3: Alignment of Incentives: Optimizing Routes of Administration
October 12th 2020EP. 4: Cost Considerations for Self- vs HCP-administered Agents
October 12th 2020EP. 5: Preferred Site of Care and Coverage for Infusions
October 12th 2020EP. 6: Utilization Management Through Medical and Pharmacy Benefit
October 12th 2020EP. 7: Cost Dispersion of Infused Drugs
October 12th 2020EP. 8: Self-injectables: Emerging Agents for the Management of MS
October 12th 2020EP. 9: Evolving Management of Drug Spending Monitoring
October 12th 2020EP. 10: Transparency Among Medical and Pharmacy Benefits
October 12th 2020EP. 11: Management of Drug Spending and Impact of COVID-19
October 12th 2020EP. 12: Future of Medical and Pharmacy Benefit Integration
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
AJMC Studies Explore the Pandemic's Impact on Telehealth, Care Access, and Patient Experience
The Impact of Cost Sharing on High-Value Care
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive